Transaction · 0000905148-26-003836

Blume-Jensen Peter

Blume-Jensen Peter, PRES, reported an open-market or private sale at Acrivon Therapeutics, Inc. involving 1229.000000 shares for an estimated $2470.29. Reported holdings after the transaction were 2244088.000000 shares. A 10b5-1 reference was not detected in the stored filing text.

Open-market sellSEC transaction code SPRES
ACRVAcrivon Therapeutics, Inc.
Trade date
Aug 18, 2026
Filing date
Aug 20, 2026
View on SEC Insider profile
Estimated value-$2.47kShares × reported price
Shares traded1.22k$2.01 per share
Holdings after2.24MDirect
% of reported position traded0.05%This security and ownership context
How reported position traded is calculated

Shares sold ÷ (holdings after + shares sold). Estimated position before: 2,245,317 shares.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

ACRV price since this filing

Daily closing prices, with the filing date and available return windows
ACRV · Daily closing priceLoading daily prices…
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago -20.5%1w ago -21.4%1d ago -7.3%
Returns since7d -2.3%30d -15.9%90d180d1y

Transaction facts

Stored Form 4 columns with their raw values

Non-derivative
Type
Sell
Code S
Identifier
0000905148-26-003836
Common Stock
Transaction date
Aug 18, 2026
Filed Aug 20, 2026, 08:07 PM · 2d delay
Shares
1,229 sh
$2.01 per share
Estimated value
-$2.47k
Computed from shares × price
Holdings after
2,244,088 sh
Direct

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $100kLarge $1.00M
Direct Ownership
Filing-only score

+10 points

Compact filing score computed from stored Form 4 facts. Version v1.

Positive filing signal

This filing has a modest positive filing-only score. Treat it as a useful flag for review, not as a buy signal.

How this score is calculated
  • direct_ownership+6 points

    direct_or_indirect_ownership = D

    Direct ownership reports the insider's personal stake.
  • timely_filing+4 points

    reporting_delay_days = 2

    Filing reported within two business days of the transaction.
Read the scoring methodology

Signed filing-only points, not a probability or expected return. Version v1.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

President and CEO

Officer YesDirector Yes10% NoOther No
Footnotes & amended
  1. F1

    Shares sold automatically to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units.

  2. F2

    These securities are held by President and CEO, Dr. Peter Blume-Jensen, who is also Dr. Kristina Masson's spouse. Dr. Masson disclaims beneficial ownership of such securities except to the extent of h…

  3. F3

    These securities are held by co-founder and EVP, Dr. Kristina Masson, who is also Dr. Blume-Jensen's spouse. Dr. Blume-Jensen disclaims beneficial ownership of such securities except to the extent of…

Original filing · 0000905148-26-003836
Related transactions

0 other transactions

Same SEC filing
Recent company activity

0 recent txs

ACRV